Morgan Stanley analyst Ravi Shanker maintains ArcBest (NASDAQ:ARCB) with a Overweight and raises the price target from $90 to $96.
Uncategorized
Morgan Stanley Maintains Overweight on ArcBest, Raises Price Target to $96
Morgan Stanley analyst Ravi Shanker maintains ArcBest (NASDAQ:ARCB) with a Overweight and raises the price target from $90 to $96.
Related Posts
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's morning session, 34 stocks hit new 52-week lows.
Why HIVE Blockchain Technologies Stock Is Trading Lower Today
HIVE Blockchain Technologies (NASDAQ: HIVE) shares are trading lower in sympathy with the price of Bitcoin and Ethereum which dipped after the People’s Bank of China said all crypto-related activities are illegal.
Provention Bio Resubmits Teplizumab Application In US For Type-1 Diabetes
Provention Bio Inc (NASDAQ: PRVB) has